Tiny bladder model reveals how to prevent recurring urinary tract infections

Recurrent urinary tract infections have long frustrated both patients and physicians, striking again and again even after seemingly successful courses of antibiotics. Now, a research team led by scientists at University College London, the University of Oxford and the University of Leicester has built a remarkable tool to investigate why these infections keep coming back: a lab-grown human “micro-bladder” that mimics the real conditions inside the urinary tract, complete with flowing urine. Their findings, published in Nature Communications, suggest that phage therapy—the use of bacteria-killing viruses—may succeed where conventional antibiotics fail, reaching hidden bacterial sanctuaries deep within the bladder wall that have never been accessible to standard drug treatments.

The scale of the problem is enormous. Urinary tract infections are among the most common bacterial infections on the planet, accounting for roughly 400 million cases every year. For most people, a UTI is a painful but passing ordeal—burning, urgency and discomfort that a short course of antibiotics usually resolves. But for a substantial minority, the infection returns with unsettling regularity. The prevailing explanation has been that the culprit bacteria, most often uropathogenic Escherichia coli, or UPEC, do not simply dwell in the urine itself. Instead, they invade the cells lining the bladder, forming protected intracellular reservoirs that act like well-defended bunkers. Antibiotics circulating in the urine may kill bacteria floating freely, but the entrenched populations inside the bladder wall survive the assault and later re-emerge to seed a fresh round of infection. Until now, researchers have had great difficulty studying this phenomenon under conditions that actually resemble the human body.

Professor Jennifer Rohn of the UCL Division of Medicine, senior author of the study, explained the core problem with traditional testing. When a patient arrives in hospital with a UTI, clinicians typically culture bacteria from the urine and test which antibiotics stop the organisms from growing. But those tests are conducted in still, nutrient-rich liquid—in an environment utterly unlike the bladder itself. In a living body, urine is constantly flowing, washing over the bladder lining in cycles of filling and emptying, and the bacteria are actively interacting with living tissue rather than suspended in a broth. An antibiotic that looks devastating in a static culture dish may perform far less impressively when confronted with flowing urine, a structured tissue barrier and bacteria that have burrowed into host cells.

Building a model that faithfully reproduces this dynamic environment has been a formidable technical challenge. Realistic bladder models tend to be too complex for routine laboratory workflows, requiring specialized equipment and expertise that most research groups lack. To overcome this, Dr Ramon Garcia Maset and colleagues at the University of Oxford engineered a novel device that can work with conventional cell cultures while recreating the flow conditions of natural urinary cycles. The resulting micro-bladder consists of human bladder tissue grown in three dimensions and exposed to a continuous, directional flow of artificial urine. This combination—living human tissue, three-dimensional architecture and fluid shear—is what gives the model its power to reveal behaviors that static cultures simply cannot capture.

The differences were striking from the moment the researchers introduced UPEC into the flowing system. Compared with bacteria grown under static conditions, the uropathogens exposed to urine flow became markedly more adhesive, gripping the bladder surface with greater tenacity. They were also more likely to invade the bladder lining, slipping inside host cells and establishing protected reservoirs of bacteria hidden within the tissue. In other words, the mechanical environment of the real bladder actively pushes the pathogen toward the very strategy—internal hiding—that makes recurrent infection so difficult to eradicate. The flow itself appears to act as a signal, prompting the bacteria to adopt their most defensive and persistent phenotype.

Armed with this realistic model, the team put standard treatment to the test. Nitrofurantoin, one of the most commonly prescribed antibiotics for urinary tract infections, performed respectably in conventional static assays. Yet inside the micro-bladder, it struggled to clear the infection completely. Bacteria lurking in the intracellular reservoirs survived the treatment, untouched by a drug that laboratory sensitivity testing had deemed effective. This single observation may help explain a paradox familiar to clinicians worldwide: patients whose infections repeatedly return despite antibiotic regimens chosen on the basis of apparently reliable susceptibility results. The standard tests, the researchers argue, are systematically blind to the sanctuary populations that matter most for relapse.

The researchers then turned to phage therapy, an approach that has attracted renewed attention as antibiotic resistance spreads. Bacteriophages are viruses that infect and destroy specific bacteria while leaving human cells unharmed, and they can be deployed in carefully selected cocktails tailored to a pathogen. Alone, the phage cocktail in this study also found it difficult to eliminate bacteria in the flowing environment—a humbling result that underscores how demanding the micro-bladder’s realistic conditions are on any therapy. But when the phages were combined with the antibiotic, the outcome improved substantially, pointing toward a two-pronged strategy in which the drugs and viruses attack the pathogen through complementary mechanisms.

The most significant finding of the study, however, concerned what phages could do that antibiotics could not. Unlike nitrofurantoin, the phage treatment measurably reduced the number of protected bacterial reservoirs within the bladder wall. This is a crucial distinction, because those reservoirs function as breeding grounds for future infection—eliminating them addresses the root cause of recurrence rather than merely suppressing the visible infection. Dr Garcia Maset, the study’s lead author, emphasized how promising this capability is: phage therapy appears able to penetrate the hidden reservoirs and root out the source of the infection, something no conventional antibiotic in the study achieved under realistic conditions.

The phages may offer yet another advantage. The researchers observed signs that phage treatment boosted the bladder tissue’s own early immune defenses, increasing the production of cytokines and chemokines—messenger proteins that coordinate inflammation and recruit immune cells to the site of infection. In effect, the viruses seem not only to kill bacteria directly but also to alert the body’s innate immune system, potentially amplifying the overall antimicrobial response. If confirmed, this immunostimulatory effect could represent a further benefit of combining phages with existing treatments.

Professor Martha Clokie, Director of the Becky Mayer Centre for Phage Research at the University of Leicester, stressed the broader methodological lesson of the work: phages must be tested under conditions that genuinely reflect the human body if their true potential is to be understood. By pairing a realistic flowing micro-bladder model with combined phage and antibiotic treatment, researchers can begin to determine how best to deploy these viruses alongside existing medicines to achieve better outcomes for patients. Her comments reflect a growing recognition across the field that many laboratory findings fail to translate because the models used to generate them bear little resemblance to living tissue.

Important caveats remain. Phage therapy is not yet a routine treatment for urinary tract infections, and considerably more research will be needed to establish how well it works in patients, how it should best be delivered, and which individuals are most likely to benefit. Clinical trials will ultimately be required to confirm whether the reservoir-clearing effects seen in the micro-bladder translate into fewer recurrences in real patients. Nevertheless, the study offers a credible and mechanistically grounded route toward longer-lasting relief for the millions of people who live with repeat infections.

In a move likely to accelerate progress across the field, the team has made the device design and the image-analysis tools developed for the study freely available to other laboratories. They hope the platform will find wider application in research exploring how flow-mediated mechanostimulation—physical forces exerted by moving fluids—affects biological systems more generally, from the gut to the vasculature. If the micro-bladder proves as illuminating for other researchers as it has been for this team, the era of testing antimicrobial therapies in environments that actually resemble the human body may have finally arrived.

News Publication Date: 4-Sep-2026

Web References: Not provided

References: Garcia Maset, R., et al. Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic Escherichia coli. Nature Communications. https://doi.org/10.1038/s41467-026-76589-y

Subject of Research: Cells

Subject of Research: Medicine

Article Title: Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic Escherichia coli

Article References: Original research article

Image Credits: AI Generated

DOI: Not provided

Keywords: urinary tract infection, phage therapy, uropathogenic Escherichia coli, micro-bladder model, antibiotic resistance, recurrent UTI, intracellular bacterial reservoirs, nitrofurantoin, urine flow, Nature Communications, bladder tissue model, cytokines

Cite Scienmag News
APA MLA Chicago

Ophelia Keating. (September 4, 2026). Tiny bladder model reveals how to prevent recurring urinary tract infections. Scienmag. https://scienmag.com/tiny-bladder-model-reveals-how-to-prevent-recurring-urinary-tract-infections/

Copy citation Download RIS

Tags: Antibiotic resistanceantibiotic resistance in urinary infectionsbacteria-killing virusesbladder wall bacterial sanctuarieshuman micro-bladder modelInner bladder wall bacterial sanctuariesInnovative diagnostic tools for UTIsinnovative infection preventionLab-grown human bladder modelslab-grown urinary tract modelMicro-bladder modelMicrofluidic models of urinary tractphage therapyPhage therapy for UTIsrecurrent urinary tract infectionsRecurrent UTI preventionTreatment strategies for recurring UTIsUPEC bacteriaUrinary tract infectionUrinary tract infection epidemiologyurinary tract infection researchUropathogenic E. coli (UPEC)UTI treatment